Cargando…

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

OBJECTIVES: Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA). METHODS: Pooled observed case analysis of data from patients with moderate-to-severe, active RA treated with rituximab in a global clinical trial programme. RESULTS: As of September 2010, 3194 patients had received...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Vollenhoven, Ronald F, Emery, Paul, Bingham, Clifton O, Keystone, Edward C, Fleischmann, Roy M, Furst, Daniel E, Tyson, Nicola, Collinson, Neil, Lehane, Patricia B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756452/ https://www.ncbi.nlm.nih.gov/pubmed/23136242 http://dx.doi.org/10.1136/annrheumdis-2012-201956

Ejemplares similares

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
por: Cohen, Stanley B, et al.
Publicado: (2010)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study
por: Peterfy, Charles, et al.
Publicado: (2016)

Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
por: Emery, Paul, et al.
Publicado: (2019)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
por: Emery, P, et al.
Publicado: (2008)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
por: Emery, P, et al.
Publicado: (2015)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2011)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
por: Emery, P, et al.
Publicado: (2017)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
por: Keystone, Edward C, et al.
Publicado: (2017)

Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis
por: Lehane, P B, et al.
Publicado: (2014)

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
por: Tak, Paul P, et al.
Publicado: (2011)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)
por: Bingham, Clifton O, et al.
Publicado: (2015)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
por: Smolen, Josef S, et al.
Publicado: (2013)

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Kay, Jonathan, et al.
Publicado: (2015)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017)

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2015)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
por: Emery, P, et al.
Publicado: (2010)

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database
por: Sokka, T, et al.
Publicado: (2009)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan
por: Murayama, Anju
Publicado: (2023)

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
por: Fleischmann, R, et al.
Publicado: (2008)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study
por: Pritchard, Charles H, et al.
Publicado: (2014)

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
por: Huizinga, Tom W J, et al.
Publicado: (2014)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
por: Genovese, Mark C, et al.
Publicado: (2014)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
por: Schoels, Monika, et al.
Publicado: (2010)

Violent deaths of media workers associated with conflict in Iraq, 2003–2012
por: Collinson, Lucie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sq7giig4jhn15e2jduia0tdt5c